Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL
Status:
Recruiting
Trial end date:
2026-04-01
Target enrollment:
Participant gender:
Summary
This is a multicenter prospective single arm phase II study, and the purpose of this study is
to evaluate the safety and efficacy of sequential treatment regimens with RO-MTX after
pomalidomide, orelabrutinib, rituximab (POR) in newly-diagnosed primary central nervous
system lymphoma, and explore the feasibility of chemo-free treatment in PCNSL. The primary
objective was the overall response rate (ORR; defined as partial response [PR] or better)
after 4 cycles of POR.
Phase:
Phase 2
Details
Lead Sponsor:
Peking Union Medical College Hospital
Collaborators:
Beijing Tiantan Hospital Sanbo Brain Hospital Capital Medical University